WO2005106488A2 - Diagnostics et therapeutique de maladies associees a l'adrenorecepteur beta-2 couple aux proteines g (adrb2) - Google Patents

Diagnostics et therapeutique de maladies associees a l'adrenorecepteur beta-2 couple aux proteines g (adrb2) Download PDF

Info

Publication number
WO2005106488A2
WO2005106488A2 PCT/EP2005/004012 EP2005004012W WO2005106488A2 WO 2005106488 A2 WO2005106488 A2 WO 2005106488A2 EP 2005004012 W EP2005004012 W EP 2005004012W WO 2005106488 A2 WO2005106488 A2 WO 2005106488A2
Authority
WO
WIPO (PCT)
Prior art keywords
adrb2
disorders
diseases
polypeptide
protein
Prior art date
Application number
PCT/EP2005/004012
Other languages
English (en)
Other versions
WO2005106488A3 (fr
Inventor
Stefan Golz
Ulf Brüggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of WO2005106488A2 publication Critical patent/WO2005106488A2/fr
Publication of WO2005106488A3 publication Critical patent/WO2005106488A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9433—(Nor)adrenaline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un ADRB2 humain qui est associé aux troubles cardio-vasculaires, aux maladies gastro-intestinales et du foie, aux maladies métaboliques, aux maladies inflammatoires, aux troubles hématologiques, aux maladies respiratoires, aux troubles neurologiques, aux troubles urologiques et aux troubles cancéreux. L'invention concerne également des dosages permettant d'identifier des composés pouvant servir à traiter ou à prévenir des troubles cardio-vasculaires, des maladies gastro-intestinales et du foie, des maladies métaboliques, des maladies inflammatoires, des troubles hématologiques, des maladies respiratoires, des troubles neurologiques, des troubles urologiques et des troubles cancéreux. L'invention concerne enfin des composés qui se lient à l'ADRB2 et/ou activent ou inhibent son activité ainsi que des compositions pharmaceutiques renfermant de tels composés.
PCT/EP2005/004012 2004-04-28 2005-04-15 Diagnostics et therapeutique de maladies associees a l'adrenorecepteur beta-2 couple aux proteines g (adrb2) WO2005106488A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04010061.2 2004-04-28
EP04010061 2004-04-28

Publications (2)

Publication Number Publication Date
WO2005106488A2 true WO2005106488A2 (fr) 2005-11-10
WO2005106488A3 WO2005106488A3 (fr) 2006-03-16

Family

ID=34966055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004012 WO2005106488A2 (fr) 2004-04-28 2005-04-15 Diagnostics et therapeutique de maladies associees a l'adrenorecepteur beta-2 couple aux proteines g (adrb2)

Country Status (1)

Country Link
WO (1) WO2005106488A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2055776A1 (fr) * 2006-11-30 2009-05-06 Arkray, Inc. Ensemble d'amorces utilisé dans l'amplification du gène de l'obésité, réactif utilisé dans l'amplification du gène de l'obésité comprenant ledit ensemble d'amorce et son utilisation
EP2115162A2 (fr) * 2007-01-19 2009-11-11 The Regents of the University of Michigan Marqueurs du cancer adrb2
WO2015121500A1 (fr) * 2014-02-17 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions pharmaceutiques destinées à être utilisées dans le traitement de la dysfonction diaphragmique induite par ventilation mécanique

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994506A (en) * 1994-08-10 1999-11-30 Human Genome Sciences, Inc. Adrenergic receptor
WO2002030268A2 (fr) * 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
US20020106739A1 (en) * 2000-11-03 2002-08-08 Oakley Robert H. Modified G-protein coupled receptors
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
US20020137081A1 (en) * 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
US20030114644A1 (en) * 2001-04-19 2003-06-19 Kinrade Michele Bennet Melanin concentrating hormone receptors
WO2004039956A2 (fr) * 2002-10-29 2004-05-13 Genentech, Inc. Compositions et methodes de traitement de maladies liees au systeme immunitaire

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994506A (en) * 1994-08-10 1999-11-30 Human Genome Sciences, Inc. Adrenergic receptor
WO2002030268A2 (fr) * 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
US20020106739A1 (en) * 2000-11-03 2002-08-08 Oakley Robert H. Modified G-protein coupled receptors
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
US20020137081A1 (en) * 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
US20030114644A1 (en) * 2001-04-19 2003-06-19 Kinrade Michele Bennet Melanin concentrating hormone receptors
WO2004039956A2 (fr) * 2002-10-29 2004-05-13 Genentech, Inc. Compositions et methodes de traitement de maladies liees au systeme immunitaire

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2055776A1 (fr) * 2006-11-30 2009-05-06 Arkray, Inc. Ensemble d'amorces utilisé dans l'amplification du gène de l'obésité, réactif utilisé dans l'amplification du gène de l'obésité comprenant ledit ensemble d'amorce et son utilisation
EP2055776A4 (fr) * 2006-11-30 2009-11-25 Arkray Inc Ensemble d'amorces utilisé dans l'amplification du gène de l'obésité, réactif utilisé dans l'amplification du gène de l'obésité comprenant ledit ensemble d'amorce et son utilisation
US8021845B2 (en) 2006-11-30 2011-09-20 Arkray, Inc. Probes for detecting obesity gene
EP2115162A2 (fr) * 2007-01-19 2009-11-11 The Regents of the University of Michigan Marqueurs du cancer adrb2
EP2115162A4 (fr) * 2007-01-19 2010-02-17 Univ Michigan Marqueurs du cancer adrb2
JP2010516256A (ja) * 2007-01-19 2010-05-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｄｒｂ２癌マーカー
US8058003B2 (en) 2007-01-19 2011-11-15 The Regents Of The University Of Michigan ADRB2 cancer markers
AU2008206168B2 (en) * 2007-01-19 2012-01-19 The Regents Of The University Of Michigan ADRB2 cancer markers
US8900819B2 (en) 2007-01-19 2014-12-02 The Regents Of The University Of Michigan ADRB2 cancer markers
WO2015121500A1 (fr) * 2014-02-17 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions pharmaceutiques destinées à être utilisées dans le traitement de la dysfonction diaphragmique induite par ventilation mécanique

Also Published As

Publication number Publication date
WO2005106488A3 (fr) 2006-03-16

Similar Documents

Publication Publication Date Title
WO2005106492A2 (fr) Diagnostic et traitement therapeutique des maladies associees au recepteur 3 de la chimiokine c-c (ccr3)
WO2005095973A2 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
WO2005103702A2 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur 2 de la chimiokine cxc (cxcr2)
WO2005106471A2 (fr) Diagnostics et therapies pour des maladies associees a un recepteur 4 de chimiokine c-c (ccr4)
WO2005101021A1 (fr) Diagnostics et therapeutiques pour maladies associees au recepteur adrenergique alpha-1d (adra1d) couple a une proteine g
WO2005076007A2 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
US20080038247A1 (en) Diagnostics and Therapeutics for Diseases Associated With G-Protein-Coupled Receptor Gpr39 (Gpr39)
US20060240436A1 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005106488A2 (fr) Diagnostics et therapeutique de maladies associees a l'adrenorecepteur beta-2 couple aux proteines g (adrb2)
US20060160132A1 (en) Diagnositics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
US20060160088A1 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40)
US20070105104A1 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2004038405A2 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2005108998A2 (fr) Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3)
WO2005059546A2 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2005040825A2 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2005078444A1 (fr) Methodes de diagnostic et de traitement de maladies associees au recepteur humain de la melatonine de type 1b (mtnr1b)
WO2005095984A2 (fr) Compositions diagnostiques et therapeutiques pour des maladies associees au recepteur adrenergique alpha 2a couple a la proteine g (adra2a)
WO2005040823A1 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur 15 couple a la proteine g (gpr15)
WO2005047905A1 (fr) Diagnostic et therapie de maladies associees au recepteur 22 couple a la proteine g (gpr22)
WO2004038421A2 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2005093427A1 (fr) Diagnostic et traitement de maladies associees au recepteur 50 associe aux proteines g (gpr50)
WO2005050199A1 (fr) Diagnostics et traitements de maladies associees au recepteur 77 lie a une proteine g (gpr77)
WO2005114201A1 (fr) Agents therapeutiques et diagnostiques pour des maladies associees au recepteur npy2 (npy2) couple a la proteine g
WO2005103681A1 (fr) Moyens diagnostiques et therapeutiques pour les maladies associees a la proteine 1 analogue au recepteur d'endotheline de type b (etbr-lp-1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase